Crescita Therapeutics Inc. (CTX.TO)
| Previous Close | 0.4300 |
| Open | 0.4350 |
| Bid | 0.4200 x 0 |
| Ask | 0.4400 x 0 |
| Day's Range | 0.4350 - 0.4350 |
| 52 Week Range | 0.3600 - 0.7300 |
| Volume | |
| Avg. Volume | 12,539 |
| Market Cap | 8.501M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireCrescita Reports First Quarter 2024 Results
LAVAL, Quebec, May 08, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2024 ("Q1-2024"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted, and in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Stan
Business WireCrescita Reports Q4 and Fiscal 2023 Results
LAVAL, Quebec, March 13, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 ("Q4-2023" and "F2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted, and in accordance with International Financial Reporting Standards ("IFRS") as issued by
Business WireCrescita Reports Third Quarter 2023 Results
LAVAL, Québec, November 08, 2023--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2023 ("Q3-2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted.
